Cistanche deserticola extract increases bone formation in osteoblasts
Yi-Chin Fong
School of Chinese Medicine
Department of Orthopaedics, China Medical University Hospital, Taichung
Search for more papers by this authorCorresponding Author
Chih-Hsin Tang
Department of Pharmacology, School of Medicine, China Medical University
Graduate Institute of Basic Medical Science
Chih-Hsin Tang, Department of Pharmacology, School of Medicine, China Medical University, no. 91, Hsueh-Shih Road, Taichung, Taiwan. E-mail: [email protected]Search for more papers by this authorYi-Chin Fong
School of Chinese Medicine
Department of Orthopaedics, China Medical University Hospital, Taichung
Search for more papers by this authorCorresponding Author
Chih-Hsin Tang
Department of Pharmacology, School of Medicine, China Medical University
Graduate Institute of Basic Medical Science
Chih-Hsin Tang, Department of Pharmacology, School of Medicine, China Medical University, no. 91, Hsueh-Shih Road, Taichung, Taiwan. E-mail: [email protected]Search for more papers by this authorAbstract
Objectives We investigated the effect of Cistanche deserticola Ma. (CD) on bone formation by cultured osteoblasts.
Methods The mineralized nodule formation assay was used to examine the in-vitro effects of CD on bone formation. Alkaline phosphatase (ALP), bone morphogenetic proteins (BMP)-2 and osteopontin (OPN) mRNA expression was analysed by quantitative real-time polymerase chain reaction. The mechanism of action of CD extract was investigated using Western blotting. The in-vivo anti-osteoporotic effect of CD extract was assessed in ovariectomized mice.
Key findings CD extract had no effect on the proliferation, migration or wound healing of cultured osteoblasts, but increased ALP, BMP-2 and OPN mRNA and bone mineralization. Mitogen-activated protein kinase (MAPK) or nuclear factor (NF)-κB inhibitors reduced CD extract-induced bone formation and ALP, BMP-2 and OPN expression. However, CD extract did not affect osteoclastogenesis. In addition, CD extract prevented the bone loss induced by ovariectomy in vivo.
Conclusions CD may be a novel bone formation agent for the treatment of osteoporosis.
References
- 1 van't Hof RJ, Ralston SH. Nitric oxide and bone. Immunology 2001; 3: 255–261.
- 2 Goltzman D. Discoveries, drugs and skeletal disorders. Nat Rev Drug Discov 2002; 10: 784–796.
- 3 Rodan GA, Martin TJ. Therapeutic approaches to bone diseases. Science 2000; 5484: 1508–1514.
- 4 Berg C et al. Teriparatide. Nat Rev Drug Discov 2003; 4: 257–258.
- 5 Ducy P et al. The osteoblast: a sophisticated fibroblast under central surveillance. Science 2000; 5484: 1501–1504.
- 6 Lane NE, Kelman A. A review of anabolic therapies for osteoporosis. Arthritis Res Ther 2003; 5: 214–222.
- 7 Rider CC, Mulloy B. Bone morphogenetic protein and growth differentiation factor cytokine families and their protein antagonists. Biochem J 2010; 1: 1–12.
- 8 Thatcher JD. The TGF-beta signal transduction pathway. Sci Signal 2010; 119: tr4.
- 9 Hong CC, Yu PB. Applications of small molecule BMP inhibitors in physiology and disease. Cytokine Growth Factor Rev 2009; 5-6: 409–418.
- 10 Styrkarsdottir U et al. Linkage of osteoporosis to chromosome 20p12 and association to BMP2. PLoS Biol 2003; 3: E69.
- 11 LEE SL. Pen-Tsao-Kun-Mu. Taipei: National Research Institute of Chinese Medicine Publications, 1986: 20.
- 12 CHIN HL et al. Study on the pharmacological effects of Cistanche deserticola Ma. China. J Chin Mater Med 1993; 31: 143–146.
- 13 HSU WH et al. Study on the chemical constituents and pharmacological effects of Cistanche deserticola Ma. and Cistanche salsa (C.A. Mey) G. Beck. Chin Tradit Herb Drugs 1995; 26: 143–146.
- 14 CHANG Y et al. Study on the strong effects of Cistanche deserticola Ma., Cistanche salsa (C.A. Mey) G. Beck and Cistanche tubulosa (Schenk) R Wight. China J Chin Mater Med 1995; 26: 143–146.
- 15 KIM JL et al. Osteoblastogenesis and osteoprotection enhanced by flavonolignan silibinin in osteoblasts and osteoclasts. J Cell Biochem 2012; 113: 247–259.
- 16 Nazrun AS et al. The anti-inflammatory role of vitamin e in prevention of osteoporosis. Adv Pharmacol Sci 2012; 25: 142702.
- 17 Lu MC. Studies on the sedative effect of Cistanche deserticola. J Ethnopharmacol 1998; 3: 161–165.
- 18 Tang CH et al. Attenuation of bone mass and increase of osteoclast formation in decoy receptor 3 transgenic mice. J Biol Chem 2007; 4: 2346–2354.
- 19 Fang SH et al. Morin sulfates/glucuronides exert anti-inflammatory activity on activated macrophages and decreased the incidence of septic shock. Life Sci 2003; 6: 743–756.
- 20 Wang YC et al. Damage formation and repair efficiency in the p53 gene of cell lines and blood lymphocytes assayed by multiplex long quantitative polymerase chain reaction. Anal Biochem 2003; 2: 206–215.
- 21 Huang HC et al. Thrombomodulin-mediated cell adhesion: involvement of its lectin-like domain. J Biol Chem 2003; 47: 46750–46759.
- 22 Tseng CP et al. Disabled-2 small interfering RNA modulates cellular adhesive function and MAPK activity during megakaryocytic differentiation of K562 cells. FEBS Lett 2003; 1-3: 21–27.
- 23 Tsai HY et al. Paeonol inhibits RANKL-induced osteoclastogenesis by inhibiting ERK, p38 and NF-kappaB pathway. Eur J Pharmacol 2008; 1: 124–133.
- 24 Schindeler A, Little DG. Ras-MAPK signaling in osteogenic differentiation: friend or foe? J Bone Miner Res 2006; 9: 1331–1338.
- 25 Mahalingam CD et al. Mitogen-activated protein kinase phosphatase 1 regulates bone mass, osteoblast gene expression, and responsiveness to parathyroid hormone. J Endocrinol 2011; 2: 145–156.
- 26 Boyce BF et al. Functions of nuclear factor kappaB in bone. Ann N Y Acad Sci 2010; 1192: 367–375.
- 27 Xu J et al. NF-kappaB modulators in osteolytic bone diseases. Cytokine Growth Factor Rev 2009; 1: 7–17.
- 28 Ruland J. Return to homeostasis: downregulation of NF-kappaB responses. Nat Immunol 2011; 8: 709–714.
- 29 Pagani F et al. Markers of bone turnover: biochemical and clinical perspectives. J Endocrinol Invest 2005; 10: 8–13.
- 30 Rachner TD et al. Osteoporosis: now and the future. Lancet 2011; 9773: 1276–1287.
- 31 Salari Sharif P et al. Current, new and future treatments of osteoporosis. Rheumatol Int 2011; 3: 289–300.
- 32 Canalis E. Growth factor control of bone mass. J Cell Biochem 2009; 4: 769–777.
- 33 Suzuki A et al. Regulation of alkaline phosphatase activity by p38 MAP kinase in response to activation of Gi protein-coupled receptors by epinephrine in osteoblast-like cells. Endocrinology 1999; 7: 3177–3182.
- 34 Jaiswal RK et al. Adult human mesenchymal stem cell differentiation to the osteogenic or adipogenic lineage is regulated by mitogen-activated protein kinase. J Biol Chem 2000; 13: 9645–9652.
- 35 Kapur S et al. Extracellular signal-regulated kinase-1 and -2 are both essential for the shear stress-induced human osteoblast proliferation. Bone 2004; 2: 525–534.
- 36 Lin FH et al. Role of mitogen-activated protein kinase in osteoblast differentiation. J Orthop Res 2011; 2: 204–210.
- 37 Alles N et al. Suppression of NF-kappaB increases bone formation and ameliorates osteopenia in ovariectomized mice. Endocrinology 2010; 10: 4626–4634.
- 38 Gupta SC et al. Inhibiting NF-kappaB activation by small molecules as a therapeutic strategy. Biochim Biophys Acta 2010; 10-12: 775–787.
